Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

5.6%

1 terminated/withdrawn out of 18 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

33%

6 trials in Phase 3/4

Results Transparency

83%

10 of 12 completed trials have results

Key Signals

2 recruiting10 with results

Enrollment Performance

Analytics

Phase 3

5(31.3%)

Phase 2

4(25.0%)

Phase 1

3(18.8%)

N/A

3(18.8%)

Phase 4

1(6.3%)

16Total

Phase 3(5)

Phase 2(4)

Phase 1(3)

N/A(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials

NCT04245176Not ApplicableCompleted

Genetic Testing for All Breast Cancer Patients (GET FACTS)

Role: collaborator

NCT05457257Phase 4Active Not Recruiting

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Role: collaborator

NCT02655016Phase 3Active Not Recruiting

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Role: collaborator

NCT04150042Phase 1Recruiting

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Role: collaborator

NCT07052266Not ApplicableRecruiting

Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening

Role: collaborator

NCT05642780Phase 2Active Not Recruiting

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Role: collaborator

NCT01982448Phase 2Completed

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Role: collaborator

NCT03076242Terminated

Genetic Evaluation of Men (GEM)

Role: collaborator

NCT03150810Phase 1Completed

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Role: collaborator

NCT03402841Phase 3Completed

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

Role: collaborator

NCT02987543Phase 3Completed

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Role: collaborator

NCT02773004Not ApplicableCompleted

Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer

Role: collaborator

NCT01891344Phase 2Completed

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

Role: collaborator

NCT01968213Phase 3Completed

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

Role: collaborator

NCT01847274Phase 3Completed

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Role: collaborator

NCT02354586Phase 2Completed

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Role: collaborator

NCT02354131Phase 1Completed

Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer

Role: collaborator

NCT03081455Completed

Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes

Role: collaborator

All 18 trials loaded